Why are the prices of new medicines so high and what can we do about it? (F8) by Angelis, Aris
  
Aris Angelis 
Why are the prices of new medicines so 
high and what can we do about it? (F8) 
 
Blog entry 
 
Original citation: 
Angelis, Aris (2016) Why are the prices of new medicines so high and what can we do about it? 
(F8). European Health Forum Gastein(30 Sep 2016) 
 
© 2016 The Author 
 
This blog was written during the European Health Forum Gastein 2016 (EHFG 2016)  
and first published on 30th of September, 2016, at: 
http://www.ehfg.org/blog/2016/09/30/why-are-the-prices-of-new-medicines-so-high-and-what-can-we-do-about-it-f8/ 
 
This version available at: http://eprints.lse.ac.uk/69845/ 
 
Available in LSE Research Online: March 2017 
 
LSE has developed LSE Research Online so that users may access research output of the 
School. Copyright © and Moral Rights for the papers on this site are retained by the individual 
authors and/or other copyright owners. Users may download and/or print one copy of any 
article(s) in LSE Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities 
or any commercial gain. You may freely distribute the URL (http://eprints.lse.ac.uk) of the LSE 
Research Online website.  
 
Why are the prices of new medicines so high and what
can we do about it? (F8)
 www.ehfg.org /blog/2016/09/30/why-are-the-prices-of-new-medicines-so-high-and-what-can-we-do-about-it-
f8/
ehfg
One issue that keeps emerging in health care meetings between decision-makers and stakeholders is the high
prices of new medicines with the EU council stating that the pharmaceutical strategies create financial pressure.
The moderator of the Innovative Medicines session in the European Health Forum Gastein started by asking the
audience a very timely question: Is it acceptable and fair that vital and innovative medicines are so upscale? The
view is rising that price levels are not sustainable, blaming manufacturers for unethical leverage of patient needs.
This has been attributed to the monopolistic power that has been provided to them due to national and
international patent rules, causing many payers and patient advocates concluding that the current
pharmaceutical R&D and pharmaceutical policy model needs replacing. Not a change of tools, but a change in
rules.
Elias Mossialos, Els Torreele, Richard Bergström, Karin Kadenbach, Ri De Ridder
There is a real decision-making problem due to the use of inadequate evidence from the very start of the
regulatory pathway, starting from licensing decisions during marketing authorisation, continuing to pricing and
reimbursement decisions in Health Technology Assessment (HTA), to treatment selection decisions between
clinicians and patients. Funding of R&D investments does not seem to follow disease burden as several
important disease areas are underfunded, whereas estimates from the German HTA agency IQWiG suggest that
approximately 65% of new drugs have no (quantifiable) added benefit. One of the unintended consequences of
the pursuit of marginal indications or “Me-Too” drugs is that it stifles innovation and creativity.
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However is this an issue for which we should only blame the pharmaceutical industry and manufacturing
companies or the regulators and competent HTA authorities as well?  And why is the price of some new
medicines so high? Some experts say that the current situation of highly expensive medicines is due to the fact
that we, society, have given industry the right to set prices as high as the market can bear.
Another line of criticisms relates to the fact that the pharmaceutical industry acts as a pure financial institution
according to which R&D spending does not reflect real R&D investment but financial speculation as in the case
of the Hepatitis C treatment Sovaldi. Or that society ends up paying twice for new medicines, first in the form of
basic research and then again for marketed products at point of care, as Nobel Prize winner Joseph Stiglitz has
indicated.
If this situation exists, then why do HTA agencies keep covering the reimbursement of such products? In the EU,
at least, the mode of evaluation has so far been based on illustrating “value-for-money” through the use of
economic evaluations such as cost-effectiveness analysis (CEA). Industry could argue that the use of
incremental cost effectiveness ratios (ICERs) has been directing the negotiation procedures at HTA level and
even shaping their clinical development programs. The pricing landscape has been set following CEA arguments
because this is what payers have so far been asking for.
Manufacturers need to be given the right signals clearly. Value preferences of decision-makers and the
appropriate stakeholders should be incorporated in a transparent and constructed way early on in the product
life-cycle of new medicines in order to influence appropriately their development, regulation, coverage and use.
 Requiring comparative evidence at marketing authorization, as part of adaptive pathways together with the use
of network meta-analyses, could be used to generate real world evidence on comparative effectiveness. This
should take place while aiming to streamline evidence needs between licensing and HTA in different countries.
There is a “wrong balance” in the area of pharmaceuticals, and blaming only the pharmaceutical industry might
be naive. Escalating and unsustainable prices of new medicines is not just a health policy or even a human
rights issue but also reveal industrial policy goals which should not be ignored. There is a political game that
relates to keeping manufacturers within national, supranational and continental boundaries. Should we use
medicines as vehicles of economic growth or as public goods?
Collectively EU countries can form the biggest collective monopsony power in the world and they should bring it
together, aiming to become informed and intelligent buyers, not lousy ones. However the starting point of
negotiations should not be set unilaterally but rationally, based on evidence and societal value preferences.
*The views are reflecting keynote presentations from Elias Mossialos (Professor of Health Policy and Director of
LSE Health at the London School of Economics and Political Science) and Els Torreele (Director of Access to
Medicines and Innovation at the Open Society Foundations), followed by a panel discussion with Richard
Bergström (Director General of the European Federation of Pharmaceutical Industries and Associations), Ri De
Ridder (Director General of the National Institute of health and Disability Insurance) and Karin Kadenbach
(Member of the European Parliament) which took place in the Innovative Medicines session on Thursday 29
September 2016 as part of the European Health Forum Gastein.
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